Wai Chun Bio-Technology Balance Sheet Health
Financial Health criteria checks 4/6
Wai Chun Bio-Technology has a total shareholder equity of HK$12.0M and total debt of HK$135.7M, which brings its debt-to-equity ratio to 1127.3%. Its total assets and total liabilities are HK$265.5M and HK$253.5M respectively. Wai Chun Bio-Technology's EBIT is HK$13.3M making its interest coverage ratio 0.8. It has cash and short-term investments of HK$61.8M.
Key information
1,127.3%
Debt to equity ratio
HK$135.71m
Debt
| Interest coverage ratio | 0.8x |
| Cash | HK$61.82m |
| Equity | HK$12.04m |
| Total liabilities | HK$253.51m |
| Total assets | HK$265.55m |
Financial Position Analysis
Short Term Liabilities: 660's short term assets (HK$133.9M) do not cover its short term liabilities (HK$179.5M).
Long Term Liabilities: 660's short term assets (HK$133.9M) exceed its long term liabilities (HK$74.0M).
Debt to Equity History and Analysis
Debt Level: 660's net debt to equity ratio (613.7%) is considered high.
Reducing Debt: 660 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 660 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 660 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 11.7% per year.